09.07.2010 • News

Merck & Co Closing Sites In Post-Merger Restructuring

Merck & Co announced plans to close eight research sites and eight manufacturing sites as it restructures in the wake of its merger with rival drugmaker Schering-Plough Corp. Merck's research network will include 16 major research and development facilities in the U.S., Belgium, England, France, Switzerland, Singapore and Japan. Merck will cut its manufacturing network from 91 facilities at the close of the deal in November to 77 facilities.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.